Citius Competitors
| CTOR Stock | 1.13 0.02 1.80% |
Citius Oncology vs Owlet Correlation
Excellent diversification
The correlation between Citius Oncology and OWLT is -0.67 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Citius Oncology and OWLT in the same portfolio, assuming nothing else is changed.
Moving together with Citius Stock
Moving against Citius Stock
| 0.64 | FTRE | Fortrea Holdings | PairCorr |
| 0.62 | FIBK | First Interstate Ban Normal Trading | PairCorr |
| 0.62 | ENS | Enersys Earnings Call This Week | PairCorr |
| 0.55 | MRVI | Maravai Lifesciences | PairCorr |
| 0.48 | APETF | Alpha Esports Tech | PairCorr |
Citius Oncology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Citius Oncology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Citius and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Citius Oncology does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Citius Stock performing well and Citius Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Citius Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SCLX | 4.23 | (1.03) | 0.00 | (0.53) | 0.00 | 10.30 | 30.71 | |||
| ACTU | 3.27 | (0.64) | 0.00 | (0.29) | 0.00 | 6.79 | 20.01 | |||
| FBRX | 5.89 | 1.51 | 0.21 | (30.32) | 6.35 | 16.12 | 40.19 | |||
| SPRO | 2.15 | (0.11) | 0.00 | (0.04) | 0.00 | 3.64 | 13.07 | |||
| APLT | 7.02 | (2.48) | 0.00 | (1.39) | 0.00 | 10.00 | 83.66 | |||
| VOR | 7.11 | (0.45) | 0.00 | 0.74 | 0.00 | 16.20 | 49.36 | |||
| MCRB | 4.43 | (0.01) | 0.00 | 0.05 | 0.00 | 9.13 | 54.10 | |||
| FATE | 3.71 | (0.35) | 0.00 | (0.14) | 0.00 | 7.27 | 20.97 | |||
| LNSR | 1.70 | 0.00 | (0.01) | 0.03 | 2.56 | 3.50 | 11.85 | |||
| OWLT | 4.03 | 0.37 | 0.06 | 2.52 | 4.94 | 8.21 | 24.32 |
Cross Equities Net Income Analysis
Compare Citius Oncology and related stocks such as Scilex Holding, Actuate Therapeutics, and Forte Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCLX | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (47.5 M) | (88.4 M) | (23.4 M) | (114.3 M) | (72.8 M) | (83.7 M) | (87.9 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| FBRX | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (33.5 M) | (38.9 M) | (49 M) | (4.1 M) | (46.5 M) | (21.7 M) | (13.9 M) | (31.5 M) | (35.5 M) | (40.8 M) | (42.8 M) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.4 M) | (93 M) | (104.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| VOR | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (10.8 M) | (43.3 M) | (68.9 M) | (92.1 M) | (117.9 M) | (116.9 M) | (105.2 M) | (100 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (113.7 M) | 136 K | 122.4 K | 128.5 K |
| FATE | (13.4 M) | (13.4 M) | (14.2 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (255.1 M) | (160.9 M) | (186.3 M) | (167.6 M) | (159.3 M) |
| LNSR | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (14.7 M) | (19.8 M) | (19.6 M) | (19.9 M) | (14.4 M) | (31.4 M) | (28.3 M) | (29.7 M) |
| OWLT | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (10.5 M) | (71.7 M) | (79.3 M) | (32.9 M) | (12.5 M) | (11.3 M) | (11.8 M) |
Citius Oncology and related stocks such as Scilex Holding, Actuate Therapeutics, and Forte Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Citius Oncology financial statement analysis. It represents the amount of money remaining after all of Citius Oncology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Citius Oncology Competitive Analysis
The better you understand Citius Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Citius Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Citius Oncology's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Citius Oncology Competition Performance Charts
Five steps to successful analysis of Citius Oncology Competition
Citius Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Citius Oncology in relation to its competition. Citius Oncology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Citius Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Citius Oncology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Citius Oncology, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Citius Oncology position
In addition to having Citius Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy Funds Thematic Idea Now
Energy Funds
Funds or Etfs investing in energy sector, natural resources, and ecology. The Energy Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Citius Stock Analysis
When running Citius Oncology's price analysis, check to measure Citius Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology is operating at the current time. Most of Citius Oncology's value examination focuses on studying past and present price action to predict the probability of Citius Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology's price. Additionally, you may evaluate how the addition of Citius Oncology to your portfolios can decrease your overall portfolio volatility.